by Plus Therapeutics | Oct 29, 2024 | LM
Mark your calendars: We will be showcasing our Leptomeningeal Metastases programs at the 2024 SNO Annual Meeting in Houston, Texas! Plus Therapeutics will present data from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal...
by Plus Therapeutics | Oct 25, 2024 | GBM
Join us at the upcoming @glioblastomaresearch Glioblastoma Patient Summit as Plus Therapeutics takes the stage! The summit will be held November 1-3 in Miami, FL, and include panel talks from neurosurgeons and neuro-oncologists as well as an opportunity to connect...
by Plus Therapeutics | Oct 8, 2024 | GBM
#ICYMI Plus Therapeutics exhibited at the #CNS2024 Annual Meeting and Dr. John Floyd presented a ReSPECT-GBM clinical trial update Key Highlights:...
by Plus Therapeutics | Oct 2, 2024 | LM
COMING SOON 🎗️💓 In honor of #BreastCancerAwarenessMonth, we are excited to announce that we will be sharing a patient testimonial from one of our Metastatic Breast Cancer patients who was treated for Leptomeningeal Metastases through the ReSPECT-LM Clinical Trial. She...
by Plus Therapeutics | Oct 1, 2024 | GBM
Plus Therapeutics presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting yesterday. Key...
Recent Comments